For laboratory research use only

HealthyWelness
Account Cart0

BPC-157 Purity Testing: How to Read a Certificate

What HPLC purity, mass spectrometry and third-party testing actually tell you about a BPC-157 lot, what they miss, and how to read a certificate of analysis.

AI illustration of autosampler vials and analytical laboratory equipment.

Cover illustration: AI-generated editorial artwork. Conceptual only; not an exact molecular structure, actual laboratory result or evidence of clinical effects.

A number like “99% purity” on a BPC-157 vial answers one narrow question: how much of the UV-absorbing material in an HPLC run was the main peak. It does not say what that peak is, how much peptide the vial contains, or whether anything invisible to the detector is present. Reading a certificate properly means knowing what each test covers and what it leaves out.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

Key points

  • HPLC purity = main peak area ÷ total peak area, in one detection method.
  • Mass spectrometry answers identity; HPLC answers homogeneity. Both are needed.
  • Net peptide content is a third, separate measurement.
  • Counter-ion and residual water are part of the powder weight but not of purity.
  • A chromatogram image is more informative than the number derived from it.

What each test tells you

TestQuestion answeredBlind spot
RP-HPLC with UVIs the material one species or several?Components that do not absorb at the chosen wavelength; co-eluting species
Mass spectrometryIs it the right molecule?Quantity; isomers of equal mass
Net peptide contentHow much peptide is in the vial?Which peptide (needs MS alongside)
Water content (Karl Fischer)How dry is the powder?Everything else
AppearanceObvious physical problemsAnything subtle

For BPC-157 specifically, MS should show 1419.5 g/mol. The peptide is well behaved analytically: an anti-doping laboratory validated a urine method with a limit of detection of 0.1 ng/mL and good linearity, and found BPC-157 stable in urine for at least four days (Cox et al., 2017). If it can be measured at sub-nanogram levels in a biological matrix, confirming it in a vial is not technically demanding.

Why purity and content differ

A lyophilized vial contains peptide, counter-ion and residual water. None of the last two shows up in an HPLC purity figure, but all of them are on the scale when the vial is filled.

ComponentCounted in HPLC purity?Counted in vial weight?
BPC-157 peptideYesYes
Counter-ion (TFA, acetate…)NoYes
Residual waterNoYes
Synthesis impurities (UV-absorbing)YesYes

Cationic peptides hold TFA tightly, and exchanging it requires specific procedures (Roux et al., 2008). Residual moisture is also controlled deliberately in lyophilized products, since too much speeds degradation and over-drying has its own drawbacks (Hsu et al., 1992). This is why net peptide content exists as a separate specification, and why it is the figure to use for molar calculations. See BPC-157 salt forms.

What impurities look like

Peptide impurities fall into two groups: those from synthesis and those from degradation. Analytical reviews describe how each is detected (Reubsaet et al., 1998).

ImpurityOriginSignature
Deletion sequencesIncomplete coupling during synthesisMass lower by one residue
Truncated peptidesPremature chain terminationSeveral residues missing
Deamidation productsStorage; Asn/Gln conversion+1 Da; often a shoulder on the main peak
Hydrolysis fragmentsStorage, especially at extreme pHSmaller masses; earlier or later elution

BPC-157 contains two aspartate residues, and Asp-containing sequences are among those most prone to hydrolysis and isomerisation, so a stability-indicating method matters more here than for an inert sequence.

Reading a certificate critically

  • Is the lot number on the report, and does it match the vial?
  • Is a chromatogram included, or only a number? A clean single peak with a flat baseline is persuasive; a number alone is not.
  • Does the MS result show the expected mass, with the deconvoluted value stated?
  • Is net peptide content reported, or only “purity”?
  • Who ran the test? An independent laboratory named on the report is stronger evidence than an unattributed in-house result.

Independent testing matters in this market. A 2024 market-surveillance study of semaglutide products sold online without prescription combined content analysis, sterility and endotoxin evaluation and LC-MS quantification of test purchases, and documented substandard products in the unregulated supply chain (Ashraf et al., 2024). That study concerned a different compound, but the methodology shows what a thorough quality assessment looks like.

What testing cannot tell you

A certificate describes the material, not its suitability. A 2026 review noted that BPC-157 has no approved formulation, no validated dosing regimen and no completed Phase II trial (Mateescu et al., 2026). A lot can be 99% pure and correctly identified while the compound itself remains investigational. Those are separate questions, and purity data should not be read as evidence about anything beyond the contents of the vial.

Lot data for our BPC-157 research peptide are published with each batch, and the peptide reconstitution calculator handles concentration maths once content is known.

Open questions

  • How consistent is net peptide content across suppliers for nominally identical vials?
  • Which degradation products dominate in BPC-157 stored as a solution, and at what rate?

Frequently asked questions

What does 99% purity mean for BPC-157?

It normally means the main peak accounts for 99% of the total UV-absorbing peak area in an HPLC chromatogram. It does not account for water, counter-ion or anything that does not absorb at the detection wavelength.

Is HPLC purity the same as peptide content?

No. Purity is the proportion of the main peak among detected components; content is how much peptide is actually in the vial. A 99% pure lot can still be well under 99% peptide by weight because of counter-ion and residual water.

What does third-party testing add?

Independence. A supplier’s own result and an outside laboratory’s result on the same lot are different kinds of evidence. The useful question is which laboratory, which methods and whether the report names the lot.

How is BPC-157 identity confirmed?

By mass spectrometry. The observed mass should match the theoretical 1419.5 g/mol. HPLC alone shows that something elutes as a single peak, not what that something is.

What does a chromatogram image show?

The separation itself: peak shape, baseline, retention time and any shoulders or minor peaks. A numeric purity figure without the chromatogram hides exactly the information that would let you judge it.

For laboratory research use only. The research materials supplied by HealthyWelness are not approved medicines, foods or cosmetics and are not for human or veterinary use. This article summarises published research and is not medical advice.

Sources

  1. Reubsaet JL, et al. Analytical techniques used to study the degradation of proteins and peptides: chemical instability. J Pharm Biomed Anal. 1998. PMID: 9884187
  2. Cox HD, et al. Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal. 2017. PMID: 28035768
  3. Roux S, et al. Elimination and exchange of trifluoroacetate counter-ion from cationic peptides: a critical evaluation of different approaches. J Pept Sci. 2008. PMID: 18035848
  4. Hsu CC, et al. Determining the optimum residual moisture in lyophilized protein pharmaceuticals. Dev Biol Stand. 1992. PMID: 1592175
  5. Ashraf AR, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. J Med Internet Res. 2024. PMID: 39509151
  6. Mateescu DM, et al. BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics. 2026. PMID: 42198317
Chat on WhatsAppMon–Sat, 09:00–21:00 (UTC+8)